Cassava Sciences reported -5120000 in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Abbott USD 5.87B 50M Jun/2025
Amgen USD 6.17B 624M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
Cassava Sciences -5120000 22.82M Jun/2025
Eisai JPY 160.05B 12.42B Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Geron 47.85M 9.45M Jun/2025
J&J USD 14.6B 816M Mar/2025
Merck USD 12.99B 224M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024